Navigation Links
New England Peptide Names Director of Chemical Development

New England Peptide, LLC (NEP), has named Robert P. Hammer, Ph.D., director of chemical development.

Gardner, Mass. (PRWEB) September 30, 2008 -- New England Peptide, LLC (NEP), has named Robert P. Hammer, Ph.D., director of chemical development.

Hammer comes to NEP from Louisiana State University (LSU), where he was the William A. Pryor professor of chemistry since 2006. Prior to 2006, he held assistant professor, associate professor, and professor positions in chemistry at the university. Before his work at LSU, Hammer completed a post-doctoral fellowship at the Swiss Federal Institute of Technology (ETH) in Zurich.

During his tenure at LSU, Hammer served as principal investigator on a number of grants from organizations including the National Science Foundation and the National Institutes of Health (NIH). He also received an NIH senior research fellowship at Purdue University, during sabbatical from LSU.

The new director is the recipient of a dozen major national and international honors and awards, including the LSU Distinguished Faculty Award; LSU College of Basic Sciences Outstanding Teacher Award; and the Lee Irvin Smith Award for High Ability and Leadership in Organic Chemistry (University of Minnesota).

Hammer is the author of nearly 100 scientific papers, including 59 research articles in refereed journals. He also has participated in the preparation of more than 60 abstracts and meeting contributions, is a frequent lecturer and holds 12 patents. His research has focused on the design, synthesis, and biophysical and biological evaluation of peptide and nucleic acid analogs, and the development of near-infrared dyes for bioconjugation. In 2006, his work on peptide analogues for inhibiting amyloid protein aggregation was recognized as part of the Scientific American 50.

A member of Phi Beta Kappa, Hammer holds a Bachelor of Science degree in chemistry, with distinction, from the University of Illinois, and a doctoral degree in organic chemistry from the University of Minnesota, where he worked with research advisor George Barany, Ph.D. Barany studied under Bruce Merrifield, the American biochemist who won the Nobel Prize in chemistry in 1984 for the invention of solid phase peptide synthesis.

"Bob brings tremendous experience and perspective in complex peptide synthesis to NEP," says Dave Robinson, NEP's CEO. "His background and research expertise perfectly complement NEP's focus on delivering discovery and preclinical services, and preparation to move into the clinical and commercial-grade peptide markets. His style and thought leadership fit well with NEP's emphasis on quality, service and culture of continuous improvement."

New England Peptide ( [ __title__ New England Peptide Web site]), founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company's chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.

Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides' inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use. All segments of the peptide market - from therapeutics and vaccines to diagnostics and cosmetics - are thriving.

# # #

Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration
2. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
3. NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
4. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
5. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology.
8. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
9. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
10. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
11. Codexis Names Vice President, Intellectual Property
Post Your Comments:
Related Image:
New England Peptide Names Director of Chemical Development
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
Breaking Biology News(10 mins):